Clinical Trials Logo

Clinical Trial Summary

Background: - About 80% of patients with hairy cell leukemia (HCL) have tumor cells that have a protein on their surface called cluster of differentiation 25 (CD25). - The experimental drug LMB-2 is a recombinant immunotoxin that has been shown to kill leukemia and lymphoma cells with the CD25 protein. (A recombinant immunotoxin is a genetically engineered drug that has two parts - a protein that binds or targets a cancer cell, and a toxin that kills the cancer cell to which it binds.) Objectives: - To evaluate the safety and effectiveness of LMB-2 in patients with HCL whose cancer cells contain the CD25 protein. - To evaluate the effects of LMB-2 on the immune system, determine how the drug is metabolized by the body and examine its side effects. Eligibility: -Adults with hairy cell leukemia whose tumor cells have CD25 on their surface Design: - Up to 27 patients may be included in the study. - Patients receive an infusion of LMB-2 through a vein every other day for three doses (days 1, 3, 5), constituting one treatment cycle. - Patients may receive up to six treatment cycles every 4 weeks unless their cancer worsens or they develop unacceptable side effects. - Blood is drawn weekly for various tests. - Before each cycle and in follow-up visits, disease status is evaluated with a physical examination, blood tests, chest x-ray and electrocardiogram. - Before the first cycle, patients may have a computed tomography (CT) scan, echocardiogram (heart ultrasound test) and bone marrow biopsy. With the patient's permission, these tests may be repeated before other cycles also.


Clinical Trial Description

Background: About 80% of patients with hairy cell leukemia (HCL) have malignant cells that express cluster of differentiation 25 (CD25) (Tac or Interleukin-2 receptor alpha (IL2Ra)). Normal resting B- and T-cells do not express CD25. LMB-2 is an anti-CD25 recombinant immunotoxin containing variable domains of MAb anti-Tac and truncated Pseudomonas exotoxin. A phase I trial at National Cancer Institute (NCI) found that the maximum tolerated dose (MTD) of LMB-2 was 40 microg/Kg intravenous (IV) given every other day for 3 doses (QOD x3). The most common adverse events were transient fever, hypoalbuminemia and transaminase elevations. In that trial, 4 of 4 patients with chemoresistant HCL had major responses, including one complete (CR) and 3 partial remissions. The patient with CR entered the trial transfusion dependent and now still has normal hemoglobin and platelet counts over 7 years later. Because HCL is more frequently cluster of differentiation 22 (CD22+) than CD25+ (100 vs 80%), HCL patients were subsequently treated with the anti-CD22 recombinant immunotoxin BL22 and no further HCL patients were treated with LMB-2. BL22 has induced 25 CRs out of 51 evaluable HCL patients. LMB-2 may be useful in patients incompletely responding to BL22, because it may distribute more evenly through extravascular sites of disease. Moreover, BL22 but not LMB-2 has caused hemolytic uremic syndrome (HUS) in 7 patients, 6 with HCL, and several of these patients could benefit by LMB-2. Thus, LMB-2 may be a useful and potentially lifesaving agent in patients who are unable to receive or who have not responded adequately to BL22. Objectives: The purpose of this study is to determine the activity of anti-Tac(Fv)-PE38 (LMB-2) in patients with CD25-expressing hairy cell leukemia (HCL). The primary endpoint of this trial is response rate. We will also evaluate response duration, LMB-2 immunogenicity, pharmacokinetics, toxicity, and monitor soluble Tac levels in the serum. Eligibility: Patients must have CD25+ HCL cells by flow cytometry, cytopenia or high circulating HCL count, prior treatment with or inability to receive BL22, prior treatment with cladribine, Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2, at least 18 years old, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) grade 0-2, albumin grade 0-1, bilirubin less than or equal to 2.2, creatinine less than or equal to 1.4 or creatinine clearance greater than or equal to 50, lack of high levels of neutralizing antibodies, lack of anti-CD25 Mab therapy for 12 weeks and other systemic treatment for 4 weeks, no prior treatment with LMB-2, lack of other uncontrolled illness including 2nd malignancy, no human immunodeficiency virus (HIV) or hepatitis C positivity, no coumadin therapy, left ventricular ejection fraction (LVEF) greater than or equal to 45%, diffusing capacity of the lungs for carbon monoxide (DLCO) greater than or equal to 55%, and forced expiratory volume 1 (FEV1) greater than or equal to 60%. Design: Patients will receive LMB-2 at 40 microg/Kg every other day (QOD) x3 at intervals of at least 25 days for up to 6 cycles. Retreatment is permitted in the absence of neutralizing antibodies or progressive disease. Patients in CR may receive 2 consolidation cycles, or 4 consolidation cycles if CR is with minimal residual disease. Dose level: LMB-2 40 microg/Kg QOD x3 Expected Accrual: 5-10 patients/year, total of 25 patients ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00321555
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase Phase 2
Start date May 2, 2006
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05645744 - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Active, not recruiting NCT03805932 - Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia Phase 1
Recruiting NCT04324112 - Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL Phase 2
Active, not recruiting NCT01711632 - BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia Phase 2
Withdrawn NCT03739606 - Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Phase 2
Active, not recruiting NCT00923013 - Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia Phase 2
Completed NCT00898079 - Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer
Completed NCT01720758 - Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease N/A
Recruiting NCT04815356 - Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant Phase 1
Recruiting NCT02131753 - Therapy Optimisation for the Treatment of Hairy Cell Leukemia Phase 2/Phase 3
Completed NCT00586924 - A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia Phase 1
Recruiting NCT06340737 - AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas Phase 1
Recruiting NCT05388123 - Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia Phase 2
Not yet recruiting NCT05859932 - Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients
Recruiting NCT04952974 - B-cell Chronic Lymphoid Malignancies Markers
Recruiting NCT00412594 - Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia Phase 2
Recruiting NCT04775745 - Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. Phase 1
Completed NCT03010358 - Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Phase 1/Phase 2
Active, not recruiting NCT01059786 - Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia Phase 2
Recruiting NCT04322383 - Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant Phase 2